Results 141 to 150 of about 53,092 (237)

3,3′,4,5′‐Tetramethoxy‐trans‐stilbene Alleviates Metabolic Dysfunction‐Associated Steatotic Liver Disease

eFood, Volume 7, Issue 4, August 2026.
3,3′,4,5′‐Tetramethoxy‐trans‐stilbene alleviates hepatic insulin resistance and metabolic dysfunction‐associated steatotic liver disease, through the activation of IRS/PI3K/Akt/GSK3β/GS and Nrf2/HO‐1 pathways, in diet‐induced obese mice. The figure was created with MedPeer (medpeer.cn).
Qiaowen Deng, Yuehan Wang, Feiyang Zheng, Manqin Fu, Chumin Zhong, Dharmani Devi Murugan, Wai San Cheang   +6 more
wiley   +1 more source

On the Origin of the Brain Semi‐Heavy Water Deuterium MR Signal Following Administration of Deuterated Metabolic Substrate: A Cautionary Tale

Magnetic Resonance in Medicine, Volume 96, Issue 2, Page 862-870, August 2026.
ABSTRACT Purpose To evaluate the extent to which the appearance of HOD in the brain following systemic administration of a deuterated substrate is due to local brain metabolism versus body metabolism. Methods [6,6‐2H2]glucose, which is transported across the blood‐brain barrier (BBB), and [6,6‐2H2]fructose (Fruc), which does not cross the BBB, were ...
Joseph J. H. Ackerman, Xia Ge, Nick Rensing, Jeffrey J. Neil, Liu Lin Thio, Joel R. Garbow   +5 more
wiley   +1 more source

Integrating spatial and chemical information enhances differentiation of non-alcoholic steatohepatitis states in Raman imaging. [PDF]

Sci Rep
Kondo R, Mizuno Y, Mochizuki K, Hashimoto K, Clément JE, Kumamoto Y, Fujita K, Harada Y, Komatsuzaki T.   +8 more
europepmc   +1 more source

Association Between Dietary Advanced Glycation End Products (AGEs) and Pancreatic Fat Accumulation: Evidence From a Case–Control Study

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 4, July 2026.
Higher dietary intake of Advanced Glycation End Products (AGEs) was associated with higher odds of pancreatic steatosis in this case–control sample of gallstone patients. ABSTRACT Background Pancreatic steatosis (PS) is a metabolic condition associated with obesity, insulin resistance, and fatty liver disease.
Mohammad Reza Shahparvari, Zahra Yari, Maedeh Chegini, Mohammad Bahrizadeh, Amir Sadeghi, Azita Hekmatdoost   +5 more
wiley   +1 more source

Retraction: Ammonia scavenger restores liver and muscle injury in a mouse model of non-alcoholic steatohepatitis with sarcopenic obesity. [PDF]

Front Nutr
Frontiers Editorial Office.
europepmc   +1 more source

Metabolic Dysfunction‐Associated Fatty Liver Disease: From Pathogenesis to Treatment

MedComm, Volume 7, Issue 7, July 2026.
Extracellular vesicles play a crucial role in interorgan crosstalk of adipose–liver and gut–liver axes and hold potential as therapeutic targets and drug delivery systems for metabolic dysfunction‐associated fatty liver disease (MAFLD). Abbreviations: AT: adipose tissue; EVs: extracellular vesicles; HL: healthy liver; NAFL: nonalcoholic fatty liver ...
Zhifu Cui, Xiaxia Du, Felix Kwame Amevor, Yaoyao Xia, You Yang, Lingbin Liu   +5 more
wiley   +1 more source

Non - Alcoholic Steatohepatitis

The Journal of Tepecik Education and Research Hospital, 1992
openaire   +2 more sources

Transcriptomics Analysis Reveals Dual Axes of Metabolic and Immune Dysregulation in the Progression of NAFLD to HCC

Natural Sciences, Volume 6, Issue 3, July 2026.
The mechanisms driving the progression of NAFLD through NASH, cirrhosis and HCC are unclear. In this study, we have comprehensively analyzed multi‐cohort transcriptomics data of the whole NAFLD spectrum to unlock the paradigm changes in gene expression and its regulation.
Anusha Patodia, Harikeshav Karthik, Sulagna Basu, Varshini Venkatesan, Rakesh Pandey, Gowri Manohari Balachander   +5 more
wiley   +1 more source

SMYD2 inhibitors have no effect in improving non-alcoholic steatohepatitis in mice. [PDF]

Front Endocrinol (Lausanne)
Yang L, Zhuo S, Zhu X, Zhang X, Wang Z, Chen Y.   +5 more
europepmc   +1 more source

Fecal Proteomics Suggest Potential Biomarkers for Non‐Alcoholic Fatty Liver Disease and Steatohepatitis

PROTEOMICS – Clinical Applications, Volume 20, Issue 4, July 2026.
ABSTRACT Background and aims Non‐alcoholic Fatty Liver Disease (NAFLD) affects about a quarter of the world's population. Liver biopsy remains the gold standard for diagnosing the progressive form of NAFLD called Non‐alcoholic Steatohepatitis (NASH) but it is invasive, prone to sampling errors and observer variability, and impractical for widespread ...
Anna Negroni, Luisa Pieroni, Noemi Fiaschini, Francesca Palone, Mariateresa Mancuso, Roberta Vitali   +5 more
wiley   +1 more source